Research and Development
Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target
August 30, 2016 Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III
Vectura asthma treatment fails at Phase III
August 30, 2016 Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura
Top ten stories in the pharmaceutical industry this week
August 26, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10
Mylan announces immediate plans to cut price of EpiPen
August 25, 2016 Medical Communications, Research and Development Mylan, clinton, epipen, increase
Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer
August 25, 2016 Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib
Positive Phase III results for Novartis MS drug
August 25, 2016 Research and Development Novartis, multiple sclerosis, phase III
Teva loses patent protection on lucrative MS treatment
August 25, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
FDA says no to Amgen’s Parsabiv
August 25, 2016 Research and Development, Sales and Marketing Amgen, FDA, par
Medical device user fees to increase 68% for 2018 to 2022
August 25, 2016 Research and Development, Sales and Marketing FDA, Medical device
Mylan latest target of US anger on drug pricing with EpiPen price increase
August 24, 2016 Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase
NICE approves lung cancer and leukaemia treatments
August 24, 2016 Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed
Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront
August 24, 2016 Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016 Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
AbbVie’s leukaemia drug granted positive opinion by MHRA through EAMS
August 23, 2016 Research and Development, Sales and Marketing
Foundation Medicine adds new immunotherapy features to its gene profiling products
August 23, 2016 Manufacturing and Production, Research and Development FoundationOne, oncology, tumour
